Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ODC1 | P11926 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7940896 | 0.79 | ODC1 (0.44) | ODC1KDM4ELMNAMAPTRAB9A | |
| SCHEMBL29001334 | 0.77 | ODC1 (0.43) | ODC1KDM4ELMNAMAPTRAB9A | |
| SCHEMBL30116554 | 0.74 | ODC1 (0.50) | ODC1KDM4ELMNAMAPTRAB9A | |
| SCHEMBL6151309 | 0.73 | ODC1 (0.41) | ODC1KDM4ELMNAMAPTRAB9A | |
| SCHEMBL6151308 | 0.73 | ODC1 (0.41) | ODC1KDM4ELMNAMAPTRAB9A | |
| SCHEMBL5069038 | 0.72 | CHRM2 (0.40) | ODC1KDM4ELMNAMAPTRAB9A | |
| SCHEMBL1249523 | 0.71 | ODC1 (0.41) | ODC1KDM4ELMNAMAPTRAB9A | |
| SCHEMBL28113559 | 0.65 | ODC1 (0.54) | ODC1KDM4ELMNAMAPTRAB9A | |
| Trifluoroacetic Acid SCHEMBL31080805 | 0.65 | ODC1 (0.48) | ODC1KDM4ELMNAMAPTRAB9A | |
| SCHEMBL15909004 | 0.63 | CES2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678305-A2 | PROTOZOAN STRAINS OF REDUCED VIRULENCE AND USE THEREOF | Institut de Recherche pour le Développement ( IRD) (FR) | 2006-07-12 | — | — | EP | claimed |
| WO-2005044844-A2 | PROTOZOAN STRAINS OF REDUCED VIRULENCE AND USE THEREOF | INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (FR) | 2005-05-19 | — | — | WO | claimed |
| EP-3554531-A1 | TREATMENT OF AGE-RELATED DEGENERATION AND OTHER EYE DISEASES WITH APOLIPOPROTEIN MIMETICS | MacRegen, Inc. (US) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018139991-A1 | TREATMENT OF AGE-RELATED DEGENERATION AND OTHER EYE DISEASES WITH APOLIPOPROTEIN MIMETICS | MACREGEN, INC. (US) | 2018-08-02 | — | — | WO | disclosed |
| EP-3204379-A1 | PYRROLIDINE AMIDE COMPOUNDS AS HISTONE DEMETHYLASE INHIBITORS | Genentech, Inc. (US) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016057924-A1 | PYRROLIDINE AMIDE COMPOUNDS AS HISTONE DEMETHYLASE INHIBITORS | GENENTECH, INC. (US) | 2016-04-14 | — | — | WO | disclosed |
| WO-2013075120-A1 | METHODS OF TREATING CANCER WITH HERBACETIN | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2013-05-23 | — | — | WO | disclosed |
| EP-2278969-A2 | INHIBITORS OF JANUS KINASES | Merck Sharp & Dohme Corp. (US) | 2011-02-02 | — | — | EP | disclosed |
| WO-2010011375-A2 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| WO-2005116050-A1 | STEROID-HORMONE CONJUGATES WITH POLYAMINES AND THEIR THERAPEUTIC USE AS ANTI-CANCER AND ANGIOSTATIC AGENTS | HUNTER-FLEMING LIMITED (GB) | 2005-12-08 | — | — | WO | disclosed |